A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 585-590

  Baghi, Mehran ^a   Hambek, Markus ^a   Wagenblast, Jens ^a   May, Angelika ^a   Wolfgang, ^a   Gstoettner, ^a   Knecht, Rainald ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Docetaxel; Recurrent head and neck cancer; TPF

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MAGNESIUM; POTASSIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SODIUM CHLORIDE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEAD AND NECK CARCINOMA; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; TREATMENT OUTCOME;

EID: 32144459527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hehr T, Classen J, Belka C et al: Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head and neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys 61: 1423-1431, 2005.
2. Ridge J: Squamous cell cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol 20: 419-429, 1993.
3. Kao J, Garofalo MC, Milano MT et al: Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev 29: 21-30, 2003.
4. Haraf DJ, Chung K, Stenson M et al: High dose re-irradiation with concomitant chemotherapy for local/regionally recurrent head and neck cancer: results in 48 patients. Proc Am Soc Clin Oncol 19: 413a, 2000.
5. Spencer SA, Harris J, Wheeler RH et al: RTOG 96-10 reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 51: 1299-1304, 2001.
6. Stevens KR Jr, Britsch A and Moss WT: High dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 29: 987-698, 1994.
7. Lee AW, Foo W, Law SC et al: Reirradiation for recurrent nasopharyngeal carcinoma:factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 38: 43-52, 1997.
8. Jacobs C, Meyers F, Hendrickson C et al: A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer 52: 1563-1569, 1983.
9. Jacobs C, Lyman G, Velez-Garcia E et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
10. Bendahmane B, Bontemps P, Bourgeois H et al: Final results of phase II study of patients with metastatic or recurrent squamous cell carcinoma of the head and neck treated with docetaxel and 5-fluorouracil. Proc Am Soc Clin Oncol 2000: 165a, 2000.
11. Forastiere AA, Metch B, Schuller DE et al: Randomized comparison of cisplatin+fluorouracil and carboplatin+ fluorouracil versus methotrexate in advanced cell carcinoma of the head and neck. J Clin Oncol 10: 1245-1251, 1992.
12. Burtness BA, Li Y, Flood W et al: Phase III trial comparing cisplatin and placebo to cisplatin and anti-epidermal growth factor antibody C225 in patients with metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 21: 901a, 2002.
13. Murphy B, Li Y, Cella D et al: Phase III study comparing cisplatin and 5-fluorouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 20: 894a, 2001.
14. Forastiere AA, Koch W, Trotti A et al: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
15. WAF1/CIP1. Br J Cancer 27: 82-85, 1996.
16. Tishler RB and Schiff PB: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22: 613-617, 1992.
17. Milas R, Saito Y and Hunter N: Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 40: 163-170, 1996.
18. Colevas A, Busse P, Norris C et al: Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL5) for squamous cell carcinoma of the head and neck. J Clin Oncol 16: 1331-1339, 1998.
19. Bernier J and Bentzen SM: Head and neck cancer management: which postoperative treatment best serves your patient? ASCO 306-312, 2003.
20. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, Van den Weyngaert D, Nguyen H, Le Bouder C, Castelijns JA, Kaanders J, De Mulder P and Vermorken JB: Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15: 638-645, 2004.
21. Janinis J, Papadakou M, Xidakis E et al: Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer. Phase II feasibility study. Am J Clin Oncol 23: 128-131, 2000.
22. Mabanta SR, Mendenhall W, Stringer SP et al: Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck 21: 591-594, 1999.
23. Rubin P: The law and order of radiation sensitivity, absolute vs. relative. In: Vaeth JM, Meyer JL (eds.). Radiation Tolerance of Normal Tissues Frontiers of Radiation Therapy and Oncology. Basel: Karger, pp. 7-40, 1989.
24. Al-Sarraf M, Pajak TF, Byhardt RW et al: Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced resectable head and neck cancers. Int J Radiat Oncol Biol Phys 37: 777-782, 1997.
25. Forastiere AA, Berkey B, Maor M et al: Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup trial 91-11. Proc Am Soc Clin Oncol 20: 2a, 2001.
26. Tishler RB, Norris Jr CM, Colevas AD et al: A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95: 1472-1481, 2002.
27. Britten RA, Perdue S, Opoku J et al: Paclitaxel is prefentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implication for paclitaxel-based chemoradiation regimens. Radiother Oncol 48: 329-334, 1998.
28. Licitra L, Grande C, Guzzo M, Mariani L, Vullo SL, Valvo F et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 21: 327-333, 2003.
29. Wendt TG, Grabenbauer G, Rodel GM et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer. J Clin Oncol 16: 1318-1324, 1998.